Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2), Rabbit Polyclonal Antibody

As low as US$317.00
Only %1 left
Catalog Number
R-183

    Product Info

  • Product Name Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2), Rabbit Polyclonal Antibody
  • Product Description google Rabbit anti-Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2) Polyclonal Antibody (Unconjugated), suitable for IHC-Frozen.
  • Alternative Names Leucine-rich repeat serine/threonine-protein kinase 2; Dardarin; LRRK2; PARK8
  • Application(s) IHC-Frozen
  • Antibody Host Rabbit
  • Antibody Type Polyclonal
  • Specificity Specificity was demonstrated by immunohistochemistry. The antibody stains positive tangles in inferior temporal cortex of human brain affected by Alzheimer's disease. This antiserum has been successfully tested in human. Other species have not yet been tested.
  • Species Reactivity Human
  • Immunogen Description A synthetic peptide (CLKRKRKILSSDDSLRSS) corresponding to amino acids 946 - 962 of the human LRRK2 protein conjugated to diptheria toxin was used as the immunogen.
  • Conjugate Unconjugated
  • Purity Description Affinity purified
  • Regulatory Status For research use only.

    Specifications

  • Product Description Rabbit anti-Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2) Polyclonal Antibody (Unconjugated), suitable for IHC-Frozen.
  • Related Products Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2-IN-1), Purified Small Molecule
  • Application(s) IHC-Frozen
  • Application Details IHC. A dilution range of 1:500 to 1:1000 is recommended. Other applications have not yet been tested. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
  • Target Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2)
  • Specificity Specificity was demonstrated by immunohistochemistry. The antibody stains positive tangles in inferior temporal cortex of human brain affected by Alzheimer's disease. This antiserum has been successfully tested in human. Other species have not yet been tested.
  • Target Host Species Human
  • Species Reactivity Human
  • Antibody Host Rabbit
  • Antibody Type Polyclonal
  • Antibody Isotype IgG
  • Conjugate Unconjugated
  • Immunogen Description A synthetic peptide (CLKRKRKILSSDDSLRSS) corresponding to amino acids 946 - 962 of the human LRRK2 protein conjugated to diptheria toxin was used as the immunogen.
  • Purity Description Affinity purified
  • Format Lyophilized
  • Reconstitution Instructions Spin vial briefly before opening. Reconstitute with 50 µL sterile-filtered, ultrapure water and centrifuge to remove any insoluble material.
  • Storage Instructions After reconstitution keep aliquots at -20°C for a higher stability, and at 2-8°C with an appropriate antibacterial agent. Glycerol (1:1) may be added for an additional stability. Avoid repetitive freeze/thaw cycles.
  • Batch Number Please see item label.
  • Expiration Date 12 months after date of receipt (unopened vial).
  • Alternative Names Leucine-rich repeat serine/threonine-protein kinase 2; Dardarin; LRRK2; PARK8
  • Uniprot Number Q5S007
  • Uniprot Number/Name Q5S007 (LRRK2_HUMAN)
  • Scientific Background LRRK2 is a member of the leucine-rich repeat kinase family. Its role is yet unknown but it may play a role in the phoshorylation of proteins central to parkinson diseases. LRRK2 contains an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a mLK-like domain and a WD40 domain. LRRK2 is present in the cytoplasm but also associates with the mitochondrial outer membrane. Defects in LRRK2 are the cause of Parkinson disease 8 (PARK8). Parkinson disease is characterised by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK8 is an autosomal-dominant late-onset parkinsonism, characterized by onset from 50 to 65 years, with slow progression and relatively benign course.
  • Shipping Temperature 25°C (ambient)
  • UNSPSC CODE 41116161
  • Regulatory Status For research use only.

    Images, Protocols & SDS

  • This antibody stains LRRK2 positive tangles in inferior temporal cortex of human brain affected by Alzheimer's disease, when used at a dilution of 1:500.

    Citations & References

  • General References Zimprich A, et al. Neuron 44:601-607(2004).
    Ota T, et al. Nat. Genet. 36:40-45(2004).